Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

Michael T. Halpern; Mary A. Cifaldi; Jordana K. Schmier

doi:10.1081/COPD-57588

Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

Michael T. Halpern, Mary A. Cifaldi, Jordana K. Schmier

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

Original language	English (US)
Pages (from-to)	217-223
Number of pages	7
Journal	COPD: Journal of Chronic Obstructive Pulmonary Disease
Volume	2
Issue number	2
DOIs	https://doi.org/10.1081/COPD-57588
State	Published - 2005
Externally published	Yes

Keywords

Bronchitis
Chronic
Clarithromycin
Costs and cost analysis
Economic
Models
Pneumonia
Respiratory tract infections

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1081/COPD-57588

Cite this

@article{d789fe6f409c4f5086376a14a38d7adb,

title = "Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections",

abstract = "We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.",

keywords = "Bronchitis, Chronic, Clarithromycin, Costs and cost analysis, Economic, Models, Pneumonia, Respiratory tract infections",

author = "Halpern, {Michael T.} and Cifaldi, {Mary A.} and Schmier, {Jordana K.}",

year = "2005",

doi = "10.1081/COPD-57588",

language = "English (US)",

volume = "2",

pages = "217--223",

journal = "COPD: Journal of Chronic Obstructive Pulmonary Disease",

issn = "1541-2555",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

AU - Halpern, Michael T.

AU - Cifaldi, Mary A.

AU - Schmier, Jordana K.

PY - 2005

Y1 - 2005

N2 - We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

AB - We used decision-analysis modeling to compare costs and outcomes of clarithromycin extended-release (Biaxin XL, Abbott Laboratories, Abbott Park, Illinois, USA) and clarithromycin immediate-release (Biaxin, Abbott Laboratories, Abbott Park, Illinois, USA) for outpatients with lower respiratory tract infections (LRTI). More patients achieved clinical cure with extended-release (83.9%) versus immediate-release (72.8%); fewer discontinued due to adverse events. Total costs with extended-release were $32 (16%) less; incorporating greater adherence for extended-release (once-daily) therapy resulted in greater savings. Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI.

KW - Bronchitis

KW - Chronic

KW - Clarithromycin

KW - Costs and cost analysis

KW - Economic

KW - Models

KW - Pneumonia

KW - Respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=22244432141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244432141&partnerID=8YFLogxK

U2 - 10.1081/COPD-57588

DO - 10.1081/COPD-57588

M3 - Article

C2 - 17136948

AN - SCOPUS:22244432141

SN - 1541-2555

VL - 2

SP - 217

EP - 223

JO - COPD: Journal of Chronic Obstructive Pulmonary Disease

JF - COPD: Journal of Chronic Obstructive Pulmonary Disease

IS - 2

ER -

Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this